Form 4: Organon & Co. CFO Matthew Walsh Receives Stock Options and Restricted Stock Units

Chief Financial Officer of Organon & Co., Matthew Walsh, reports the acquisition of stock options and restricted stock units.

Summary

• On March 29, 2024, Matthew Walsh, the Chief Financial Officer of Organon & Co., was granted 45,212 restricted stock units (RSUs) and 185,185 stock options.
• The RSUs represent a contingent right to receive one share of Organon common stock for each RSU.
• The RSUs vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• The stock options, with an exercise price of $18.8, also vest in three equal installments on the same dates as the RSUs: March 29, 2025, March 29, 2026, and March 29, 2027.
• Following these transactions, Walsh directly owns 45,212 RSUs and 185,185 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is slightly positive due to the incentive structure.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

This type of equity compensation is common for executives in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Equity compensation packages for CFOs in the pharmaceutical industry typically include a mix of stock options and restricted stock units.
• The vesting schedule of three years is a standard practice to ensure executive retention.
• Comparing the size of the grant to similar companies like Viatris or Teva Pharmaceuticals would provide further context on the competitiveness of the compensation package.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the executive leadership.

Key Dates